Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET
Company Participants
Chris Taylor - Vice President, Investor Relations and Corporate Communications
Brian Goff - Chief Executive Officer
Sarah Gheuens - Chief Medical Officer and Head, R&D
Tsveta Milanova - Chief Commercial Officer
Cecilia Jones - Chief Financial Officer
Conference Call Participants
Gregory Renza - RBC Capital Markets
Divya Rao - TD Cowen
Eric Schmidt - Cantor
Alec Stranahan - Bank of America
Tessa Romero - JPMorgan
Danielle Brill - Raymond James
Operator
Good morning, and welcome to Agios’ First Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded at Agios’ request. I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for Agios. Please begin.
Chris Taylor
Thank you, operator. Good morning, everyone, and welcome to Agios’ conference call and webcast to discuss first quarter 2024 financial results and recent business highlights. You can access slides for today’s call by going to the Investors section of our website, agios.com.
On today’s call, I’m joined by our Chief Executive Officer, Brian Goff; Dr. Sarah Gheuens, Chief Medical Officer and Head of R&D; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, Chief Financial Officer.
Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual results and events could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.
And with that, I’ll turn the call over to Brian.
Brian Goff
Good morning, everyone, and thank you for joining us. Our mission at Agios is to develop and deliver transformative medicines that elevate and extend the lives of patients living with rare diseases, and we are off to a fast start in 2024. Our foundation today leverages mitapivat’s novel mechanism of action, which focuses on overall red blood cell health, and has been a key driver for our recent clinical results.
On January 3, we reported positive data from the Phase 3 ENERGIZE study of our lead PK activator, mitapivat, marketed as PYRUKYND, in patients with non-transfusion-dependent thalassemia. This study met both the primary endpoint of hemoglobin response rate as well as both key secondary endpoints associated with change from baseline in FACIT-Fatigue score and average hemoglobin concentration, and we look forward to presenting these data at an upcoming medical meeting.